Labiotech.eu

Interview 27 Sep 2017

What’s this Top Swiss VC Up To These Days? General Partner Tells All

Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

German Researchers’ Algorithm Can Predict New Targets for Existing Drugs

An algorithm based on the brain’s self-organizing capacity has been developed in Germany that could combat the rising costs of drug development. A team at TU Dresden has pioneered an algorithm that exploits the self-organization of the brain to predict new drug targets, without the need for extra biological or molecular information. The study, published in Briefings […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

French Gene Therapy for Wilson’s Disease gets Orphan Status

Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first gene therapy for Wilson’s disease. Seeing its potential, both the FDA and the EC have decided to grant […]

September 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Sep 2017

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

Janssen’s single-tablet regimen, Symtuza, has been approved by the European Commission for the treatment of HIV in adults and adolescents in the EU. The pharmaceutical arm of Johnson & Johnson, Janssen, has announced that the European Commission has approved its single-tablet regimen (STR), Symtuza, to treat Human Immunodeficiency Virus (HIV) infections. Previous studies have demonstrated […]

September 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […]

September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 27 Sep 2017

How to Survive the Valley of Death: Tips from Europe’s Largest Research Hospital

Taking research from the bench to the bedside is an infamous graveyard in biotech. Researchers from Charité and their colleagues have a plan to help startups survive. “Many basic research approaches currently fail far too late in their development,” write researchers from Charité University Hospital, based here in Berlin, in collaboration with colleagues from the University […]

September 27, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2017

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […]

September 26, 2017 - 3 minutesmins - By Alex Dale

News and Trends 26 Sep 2017

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […]

September 26, 2017 - 2 minutesmins - By Alex Dale

Best in Biotech 26 Sep 2017

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […]

September 26, 2017 - 8 minutesmins - By Evelyn Warner

Eligo Bioscience Microbiome CRISPR Bacteriophage

News and Trends 26 Sep 2017

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […]

September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Sep 2017

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […]

September 25, 2017 - 1 minutemin - By Alex Dale

News and Trends 25 Sep 2017

Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains

Sanofi, in collaboration with the US National Institute of Health, is developing an antibody HIV treatment that can kill 99% of strains. Human immunodeficiency virus (HIV) is notoriously difficult to treat as it mutates so quickly. Some patients develop ‘broadly neutralizing antibodies’ that attack fundamental parts of the virus, and are therefore very powerful tools. Researchers […]

September 25, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What’s this Top Swiss VC Up To These Days? General Partner Tells All

German Researchers’ Algorithm Can Predict New Targets for Existing Drugs

French Gene Therapy for Wilson’s Disease gets Orphan Status

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

How to Survive the Valley of Death: Tips from Europe’s Largest Research Hospital

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies

Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!